EL PASO, Texas--(BUSINESS WIRE)--Premier Biomedical, Inc. (OTCQB: BIEI) announced that they have filed an application with the U.S. Patent Office on a novel approach to the treatment of Cockayne Syndrome.
Cockayne Syndrome (CS) is a rare and devastating neurodegenerative disorder characterized by slow growth, premature aging (progeria), shortened lifespan, moderately to severely inhibited neurological development, hearing loss, eye abnormalities/blindness, and sensitivity to sunlight. Cockayne Syndrome is caused by an inherited gene mutation.
Mitchell S. Felder, M.D., the Chairman of Premier’s Scientific Advisory Board, and a board certified attending neurologist, stated, "The physiologic basis of Cockayne Syndrome is a dysfunction in autophagy, the intracellular "cleanup crew". Recent medical articles have shown autophagy to be a major cause of Parkinson's Disease, Alzheimer's Disease and aging. I deeply believe that by beating Cockayne Syndrome we will also make major therapeutic breakthroughs against Parkinson's Disease, Alzheimer's Disease, and even aging. This patent application will serve as a detailed and specific roadmap for achieving those major breakthroughs."
About Premier Biomedical, Inc.
Premier
Biomedical, Inc. is a research-based company that intends to discover
and develop medical treatments for a wide range of diseases in humans.
Premier has licensed the technology behind multiple patents/patent
applications in the United States and Europe in the areas of Cancer,
Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered
with the Department of Defense with Center of Expertise at the William
Beaumont Army Medical Center and the University of Texas at El Paso
(UTEP). The company's R&D efforts are centered in El Paso, TX and their
business offices are in Western Pennsylvania. The Company's common stock
trades on the fully reporting Over-The-Counter Bulletin Board under the
ticker symbol "BIEI."http://www.premierbiomedicalinc.com/
Safe Harbor Notice
Certain statements contained
herein are “forward-looking statements” (as defined in the Private
Securities Litigation Reform Act of 1995). Premier Biomedical, Inc.
cautions that statements, and assumptions made in this news release
constitute forward-looking statements and makes no guarantee of future
performance. Forward-looking statements are based on estimates and
opinions of management at the time statements are made. These statements
may address issues that involve significant risks, uncertainties,
estimates made by management. Actual results could differ materially
from current projections or implied results. Premier Biomedical, Inc.
undertakes no obligation to revise these statements following the date
of this news release.